Top Page
Pharma Mar SA
(BME:PHM)
Pharma Mar SA (PHM) vs. iShares MSCI Spain ETF (EWP)
Pharma Mar SA Business Overview & Revenue Model
Pharma Mar SA Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 175.75M | 174.85M | 158.15M | 196.34M | 229.83M | 269.96M | Gross Profit |
| 165.93M | 166.67M | 148.54M | 182.70M | 213.39M | 256.24M | EBIT |
| 6.56M | 6.47M | -3.83M | 44.07M | 92.45M | 155.94M | EBITDA |
| 21.93M | 21.23M | 4.55M | 52.07M | 104.08M | 155.94M | Net Income Common Stockholders |
| 19.88M | 26.13M | 1.14M | 49.36M | 92.86M | 137.26M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 140.85M | 154.53M | 162.56M | 182.42M | 201.88M | 195.52M | Total Assets |
| 333.50M | 349.64M | 340.52M | 393.26M | 368.39M | 330.26M | Total Debt |
| 51.94M | 51.08M | 43.67M | 42.63M | 49.33M | 56.66M | Net Debt |
| -8.35M | -12.16M | -16.36M | -107.18M | -64.02M | -39.55M | Total Liabilities |
| 136.02M | 141.28M | 147.08M | 170.30M | 190.47M | 227.54M | Stockholders Equity |
| 197.47M | 208.36M | 193.44M | 222.96M | 177.92M | 102.72M |
| Cash Flow | Free Cash Flow | ||||
| -18.29M | -9.48M | -29.40M | 29.47M | 17.87M | 275.94M | Operating Cash Flow |
| -9.56M | 6.03M | -13.45M | 38.32M | 25.68M | 278.94M | Investing Cash Flow |
| 39.33M | 1.03M | -43.05M | 10.88M | 18.47M | -119.01M | Financing Cash Flow |
| -5.43M | -5.35M | -32.14M | -13.37M | -27.41M | -73.82M |
Pharma Mar SA Technical Analysis
Pharma Mar SA Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.65B | 81.12 | 10.15% | 0.71% | 8.39% | 947.08% | |
54 Neutral | $5.38B | 3.31 | -45.11% | 3.29% | 16.82% | 0.04% | |
| €2.38B | 232.50 | 0.69% | 1.34% | ― | ― | ||
| €1.35B | 12.10 | 16.04% | 2.94% | ― | ― | ||
| €6.43B | 27.01 | 3.37% | ― | ― | ― | ||
| €265.95M | 23.59 | 5.11% | 1.24% | ― | ― | ||
| €2.86B | 20.65 | 25.24% | 1.59% | ― | ― |
Pharma Mar SA Corporate Events
Pharma Mar SA announced positive results from the phase 3 IMforte study, showcasing the effectiveness of Zepzelca® (lurbinectedin) combined with atezolizumab as a first-line maintenance treatment for advanced-stage small cell lung cancer (SCLC). The study demonstrated significant improvements in progression-free and overall survival, marking a potential new standard in SCLC treatment. The results were presented at the ASCO meeting and published in The Lancet, with a marketing authorization application submitted to the European Medicines Agency.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar SA has reported on its share buy-back program activities conducted between May 19 and May 23, 2025. During this period, the company purchased a total of 6,500 shares at varying prices on the BME trading center. This buy-back initiative is part of the company’s strategy to stabilize its stock and potentially enhance shareholder value.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
PharmaMar has submitted a marketing authorization application to the European Medicines Agency for Zepzelca® in combination with atezolizumab for first-line maintenance treatment in adult patients with advanced-stage small cell lung cancer. This application is based on significant results from the Phase 3 IMforte trial, highlighting the potential impact on PharmaMar’s operations and its positioning in the oncology market.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar SA has reported on its recent share buy-back program activities conducted between May 12 and May 16, 2025. This initiative is part of the company’s strategy to stabilize its stock and potentially enhance shareholder value, reflecting a proactive approach to managing its market presence.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar S.A., along with its partner Adium Pharma S.A., has received conditional marketing approval in Argentina for Zepzelca® (lurbinectedin) for the treatment of metastatic small cell lung cancer (SCLC). This approval, based on clinical trial data, expands the availability of lurbinectedin to 18 territories globally, reinforcing Pharma Mar’s position in the oncology market and providing a new treatment option for a particularly aggressive form of lung cancer.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar SA, in partnership with Adium Pharma SA, has received conditional marketing approval in Argentina for Zepzelca® (lurbinectedin) to treat metastatic small cell lung cancer (SCLC) in adults. This approval, based on clinical trial data, expands the availability of lurbinectedin to 18 territories globally, highlighting its growing impact in cancer treatment markets, particularly in Latin America.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
Pharma Mar S.A. has announced the convening of its Ordinary General Shareholders’ Meeting, scheduled for June 18, 2025, at the Villa de Colmenar Viejo Municipal Auditorium in Madrid. The meeting will address several key agenda items, including the approval of annual accounts, management reports, and a proposal for dividend distribution. Additionally, the re-election of a director and the approval of a new share delivery plan for employees are on the agenda, indicating the company’s focus on strategic governance and employee engagement.
PharmaMar Group reported a 19% increase in recurring income, reaching 37.8 million euros in Q1 2025, driven by strong sales of lurbinectedin in Europe and the U.S. The company also saw a 22% rise in net sales and a 16% increase in royalty income. Despite a decrease in R&D investment, the financial results reflect positive growth in the oncology segment, with implications for sustained market presence and stakeholder confidence.
Pharma Mar, S.A. has announced the convening of its Ordinary General Meeting of Shareholders, scheduled for June 18, 2025. Key agenda items include the approval of the Annual Accounts, Management Reports, and a proposal for a dividend distribution. The meeting will also address the re-election of a director, authorization for share acquisitions, and a new share delivery plan for employees, reflecting the company’s strategic focus on governance and stakeholder engagement.
Pharma Mar SA has reported on its recent share buy-back program activities conducted between April 14 and April 17, 2025. The company purchased a total of 1,600 shares at the BME trading center, with weighted average prices ranging from 75.00000 to 75.62000 per share, as part of its ongoing efforts to stabilize and manage its treasury stock.
Pharma Mar SA announced the suspension of its liquidity contract with JB Capital Markets, effective February 28, 2025, following the completion of a share buyback program and the initiation of a new one. This move is part of the company’s ongoing efforts to manage its share liquidity and optimize shareholder value, reflecting strategic financial maneuvers that may impact its market positioning and investor relations.
The rating agency EthiFinance Ratings has maintained Pharma Mar, S.A.’s long-term credit rating at ‘BB+’ with a stable outlook, indicating confidence in the company’s financial stability.
Pharma Mar SA has entered into an exclusive license agreement with Merck for the development and commercialization of Zepzelca® (lurbinectedin) in Japan, targeting small cell lung cancer (SCLC). This collaboration will provide Pharma Mar with an initial payment of 22 million euros and potential additional earnings of up to 31 million euros through milestone achievements, while allowing Merck to leverage its market expertise to introduce the drug in Japan, expanding its availability to patients across Asia-Pacific regions.
Pharma Mar, S.A. has announced the execution of a Share Delivery Plan aimed at employees and executives, excluding board members, to encourage participation in the company’s share capital and incentivize retention. The plan involves delivering up to 41,000 shares from treasury stock, with a total value of 832,553.87 euros, and includes a lock-up period of three years, partially lifting after 18 months. This initiative is expected to strengthen employee commitment and align interests with the company’s long-term goals.
Sylentis, a subsidiary of Pharma Mar, has been awarded a 21.1 million euro grant from the European Commission under the IPCEI ‘Med4Cure’ program. This funding will support the SYOLIGO project, which involves the construction of a new pharmaceutical plant in Getafe, Spain, for the production of RNA-based drugs and treatments for rare diseases. The project is expected to create 86 direct and 350 indirect jobs by 2030, enhancing Spain’s pharmaceutical capabilities and fostering collaboration with European partners.
PharmaMar’s Board of Directors has proposed a 23% increase in the dividend to 0.80 euros per share, reflecting the company’s financial strength and commitment to shareholder value. This marks the sixth consecutive year of dividend distribution, with a total accumulated amount exceeding 70 million euros, highlighting the company’s robust financial performance with an 11% revenue growth in 2024.